SlideShare ist ein Scribd-Unternehmen logo
1 von 43
BY SAYEDA SALMA
1ST M PHARM
What is supac ?
In the process of developing the new product ,
the batch size used in earliest human studies are
small.
The sizes of the batch is gradually increased(scale
up).
The scale up and the changes made after approval
in the composition, manufacturing process ,
manufacturing equipment and change of site have
become known as scale up and post approval
changes (supac).
SUPAC
The FDA has issued various guidance for supac changes
designated as:
Supac-IR ( for immediate release solid oral dosage
form).
Supac-MR (for modified release solid oral dosage
form).
Supac-SS (for non sterile semisolid dosage form
including creams, ointments, gels and lotions).
Supac guidelines-define
Level of
changes
• Minor changes
• Moderate changes
• Major changes
filing
• Annual report
• Changes being affected supplement
• Prior approval supplement
tests
• Application/compendial tests
• In-vitro dissolution/release
• In-vivo
Level of changes
Likelihood of impact on formulation quality and performance:
• Level 1: Those changes that are unlikely to have any detectable
impact on formulation quality and performance.
• Example- Changes in the colour, flavours, Changes In the
excipient expressed as percentage (w/w) of total formulation,
less than or equal to the following range .
• Level2: Changes are those that could have significant
impact on the formulation quality and performance.
• Example -Changes in the technical grade of excipient
(Avicel PH102 vs Avicel PH200) Changes expressed as
percent (w/w of total formulation) .
• Level3:
 Level 3 : changes are those that are likely to have significant
impact on formulation quality and performance.
Example -Any qualitative or quantitative excipient changes a
narrow therapeutic drug beyond the range for level 1 and All
other drug not meeting the dissolution criteria as level 2.
These guidelines provide recommdation for post
approval changes in:
• In component or compostion
• The site of manufacture
• The scale up of manufacture
• The manufacturing(process and equipment)
Component and composition
changes
SUPAC-IR:
 Focus on changes in the amount of excipients in the
drug product.
SUPAC-MR:
 Excipient critical or non critical to the drug release. -
Changes in non release controlling excipients - Changes
in release controlling excipients.
SUPAC-SS:
 Changes in preservative.
SUPAC-IR ( components
and composition)
SUPAC-IR
• 1)Focus on the changes in amount of
excipients in the drug product.
• 2)Not focus on change in the amount of the
drug substance .
LEVEL CLASSIFICATION EXCIPIENT
RANGES (%w/w
of total
formulation)
TEST
DOCUMENTATION
FILING
DOCUMENTA
TION
1) • Delition or
partial
delition of an
ingredient
(colour ,
flavor or
change in
ingredient of
the ink).
• -Changes in
excipients,
expressed as
% (w/w) of
total
formulation,
less than or
equal to
excipient.
 Filler
 ±5
Disintegrant
 Starch
 ±1 Binder
 ±0.5 Lubricant
 Calcium
(Ca)or
Magnesium
 (Mg) Stearate
±0.25
 stability
 Application/Co
mpendial
requirements
 Annual report
LEVEL CLASSIFICATION EXCIPIENT
RANGES (%w/w of
total formulation)
TEST
DOCUMENTATION
FILING
DOCUMEN
TATION
2)  Change in
technical
grade of
excipient.
 Changes in
excipients,
expressed as
% (w/w) of
total
formulation,
greater than
Level 1
changes.
 Filler
 ±10
Disintegrant
 Starch
 ±6 Other
 ±1 Binder
 ±1 Lubricant
 Calcium (Ca) or
 Magnesium (Mg)
 Stearate ±0.5
 Other
±2 Glidant Talc
±2 Other
±0.2
 -stability
application/co
mpendial
requirements.
 Dissolution
data depends
on solubility,
therapeutic
range and
permeability.
 Case A(hp-hs)
 Case B(lp-hs)
 Case C(hp-ls)
•Prior
approval
supplement
•Annual report
LEVEL CLASSIFICATION TEST DOCUMENTATION FILING
DOCUMENTATION
3)  Higher than SUPAC-
IR.
 Level 1 and Level 2
excipient ranges.
 stability
application/compend
ial requirements.
 Case B dissolution
profile (Multi-point
dissolution profile in
the application
/compendial medium
at 15, 30, 45, 60,
and 120 minutes or
until an asymptote is
reached for the
proposed and
currently accepted
formulation).

 Biostudy or IVIVC
•Prior approval
supplement.
•Annual report.
SUPAC-MR (components
and composition)
SUPAC-MR
Components and composition of non-release controlling
excipient and release controlling excipient.
 Focuses on changes to non-release controlling excipients.
 Changes in components or composition that have the
effect of adding a new excipient or deleting an excipient
are defined at level 3.
Non-release controlling excipient
LEVEL CLASSIFICATION TEST DOCUMENTATION FILING
1)  Delition or partial
delition of an
ingredient –up to
SUPAC-IR Level 1
excipient ranges.
 stability-
application/compen
dial requirements.
 Annual report
LEVEL 2
2)  change in
technical grade
of excipients
 up to SUPAC-IR
Level 2
excipient
ranges
 stability
application/compen
dial requirements.
 Multi-point
dissolution profiles
(15,30,45,60 & 120
min) USP buffer
media at pH 4.57.5
for extended
release) Three
different Media
(e.g., Water, 0.1N
HCl, and USP buffer
media at Ph 4.5
And 6.8 for delayed
release)
•Prior
approval
supplement.
•Annual report
LEVEL 3
3)  Higher than
SUPAC-IR
Level 1 and
Level 2
excipient
ranges.
 -stability
application/compen
dial requirements.
 Biostudy or IVIVC
 Prior approval
supplement
SUPAC-MR (release controlling
excipient)
LEVEL CLASSIFICATION TEST DOCUMENTATION FILING
DOCUMENTATION
1)  ≤ 5% w/w change
based on total
release
controlling
excipient
content.
 No other changes
 Stability
 application/compendi
al requirements
 Annual report
LEVEL 2
2)  change in
technical grade
of excipients.
 ≤ 10% w/w
change based
on total release
controlling
excipient
content.
 stability
application/compendi
al requirements.
 Multi-point dissolution
profiles (15,30,45,60
& 120 min) USP buffer
pH 4.5-7.5 for
extended release)
Three different Media
(e.g., Water, 0.1N
HCl, and USP buffer
media at Ph 4.5 And
6.8 for DR release)
 Prior
approval
supplement
 Annual
report
SUPAC-SS (components
and composition)
SUPAC-SS
• for non sterile semisolid dosage form including
creams , ointments , gels and lotions.
SUPAC-SS (Components and
composition)
LEVEL CLASSIFICATION TEST
DOCUMENTATION
FILING
DOCUMENTATION
1)  Delition or partial
delition of an
ingredient.
 change in supplier or
technical grade of
any other excipient.
 Up to 5 % change in
approved amount of
ingredient
 Stability
 application/
compendial
requirements
 Annual report
LEVEL 2
2)  Upto >5 % and ≤ 10
% change in
approved amount of
ingredient.
 Change in particle
size distribution of
the drug substance,
if the drug is in
Suspension.
 change in supplier
or technical grade
of any other
excipient
 stability
application/compe
ndial requirements
 in vitro release
test
 Changes
being
effected
supplement
 Annual
report
LEVEL 3
3)  change in approved
amount of
ingredient.
 Change in
crystalline form of
ingredient
 Stability
 application/comp
endial
requirements
 Prior
approval
supplement
SUPAC-SS (preservative)
LEVEL CLASSIFICATION TEST
DOCUMENTATION
FILING
DOCUMENTATION
1) Quantitatively 10% or
less change in the
approved amount of
preservative.
 application/comp
endial
requirements
 Preservative
effectiveness test
at lowest
specified
preservative level
Annual report
LEVEL 2
2)  10% -20 % change in
the approved
amount of
preservative
 application/comp
endial
requirements.
 Preservative
effectiveness test
at lowest
specified
preservative level
 Changes
being
effected
supplem
ent
 Annual
report
LEVEL 3
3)  > 20% change in
the approved
amount of
preservative
(including
deletion) or use of
a different
preservative.
 application/compen
dial requirements -
executed batch
records.
 For new
preservative,
analytical method
for identification
and assay validation
studies.
 Preservative
effectiveness test at
lowest specified
preservative.
 Prior
approval
supplement
 Annual
report
Site changes
It includes the changes in location of the site
of manufacturing facilities for both company
owner and contract manufacturer.
It does not include scale up
LEVEL 1
LEVEL CLASSIFICATION TEST
DOCUMENTATION
FILING
DOCUMENTATION
1)  Site change within a
single facility.
 No change in SOP,
environmental
conditions or
equipment's used.
 Common personnel's
 application/co
mpendial
requirements
Annual report
Level 2
2)  Same
continuous
campus
 Common
personnel
 No other
changes
 application/compendial
requirements.
 Notification of Location of
new site
 Updated batch records.
 SUPAC – MR : Multi-point
dissolution profiles
(15,30,45,60 & 120 min) USP
buffer media at pH 4.5-7.5 for
extended release) Three
different Media (e.g., Water,
0.1N HCl, and USP buffer
media at Ph 4.5 And 6.8 for
delayed release)until 80% of
Drug Released.
 Annual
report
 Changes
being
Effected
Supplement
LEVEL 3
3)  Different
campus
 Different
personnel
 application/compendial
requirements
 Notification of Location of new
site
 Updated batch record
 SUPAC –IR : Multi-point
dissolution profile in the
application and compendial
medium
 SUPAC – MR : Multi-point
dissolution profiles (15,30,45,60
& 120 min) USP buffer media at
pH 4.5-7.5 for extended release)
Three different Media (e.g.,
Water, 0.1N HCl, and USP buffer
media at Ph 4.5 And 6.8 for
delayed release).
 Annual
report
 Prior
approval
supplement
Change in
batch size
(scale up of
manufacture)
Post approval changes in the size of a
batch from the pivotal/pilot scale
biobatch material to larger or smaller
production.
Post
Scale down below 1,00,000 dosage
units is not covered by this guideline.
Scale
down
Scale up changes should be properly
validated and if needed, inspected by
appropriate agency personnel.
Scale
up
Level 1
LEVEL CLASSIFICATION TEST DOCUMENTATION FILING
DOCUMENTATION
1)  Change in batch
size, up to and
including a
factor of 10
times the size
of the
pilot/biobatch
 Updated batch records
application/compendial
requirements stability
Annual report
Level 2
2)  Changes in
batch size
beyond a factor
of ten times the
size of the pilot
or biobatch
 No other
changes
 -Updated batch records -
application/compendial
requirements
 Stability
 SUPAC –IR Multi-point
dissolution profiles.
 SUPAC – MR -Multi-point
dissolution profiles in multiple
medias (e.g., USP buffer
media at pH 4.5-7.5 for
extended release) three other
media (e.g., Water, 0.1N HCl,
and USP buffer media at Ph
4.5 And 6.8 for delayed
o Annual
report
o Changes
being
effected
by
suppleme
nt
MANUFACTURING CHANGES
(equipment)
LEVEL CLASSIFICATION TEST DOCUMENTATION FILING
DOCUMENTATION
1)  Alternate
equipment of
same design and
principles
Automated
equipment's
 Updated batch records
 application/compendial
requirements stability
Annual report
LEVEL 2
2)  Change to
equipment of
different design
and principle
 Updated batch records
application/compendial
requirements
 Stability
 SUPAC –IR Multi-point
dissolution profiles in
multiple medias
 SUPAC – MR -Multi-point
dissolution profiles in
multiple medias
 Annual
report
 Changes
being
Effected
Suppleme
nt
MANUFACTURING CHANGES
(PROCESS)

LEVEL CLASSIFICATION TEST DOCUMENTATION FILING
DOCUMENTATION
1)  Adjustment
of equipment
operating
conditions
(operating
speeds,
mixing times)
 Within
approved
application
ranges
 Updated batch records
 application/compendial
requirements
 Stability
Annual report
LEVEL 2
2)  Adjustment of
equipment
operating
conditions
(operating
speeds,
mixing times)
 Beyond
approved
application
ranges
 SUPAC – SS
Change in the
process of
combining two
phases
 -Updated batch records -
application/compendial
requirements
 Stability
 SUPAC-IR Multi-point
dissolution profile.
 SUPAC-MR -Multi-point
dissolution profiles in
multiple medias (e.g., USP
buffer media at pH 4.5-7.5
for extended release) three
other media (e.g., Water,
0.1N HCl, and USP buffer
media at Ph 4.5 And 6.8 for
delayed release).
 SUPAC-SS In vitro release
test Documentation.
 Annual
report
 Changes
being
Effected
Suppleme
nt
LEVEL 3
3)  Changes in
the type of
process
used (e.g.
wet
granulation
to direct
compressio
n
 Updated batch records -
application/compendial
requirements -Stability -
Biostudy or IVIVC.
 SUPAC-IR Multi-point
dissolution profile.
 SUPAC-MR Multi-point
dissolution profiles in
multiple medias (e.g., USP
buffer media at pH 4.5-7.5
for extended release) three
other media (e.g., Water,
0.1N HCl, and USP buffer
media at Ph 4.5 And 6.8 for
delayed release)
 Prior
approval
supplement
 Annual
report
LIMITATIONS OF SUPAC
• Supac has not been updated ( 1995/97 for main
guidelines )
• Does not discuss multiple changes
• Does not cover modified equipment
• Must be used in conjunction with other references
ex: excipient handbook.
Supac

Weitere ähnliche Inhalte

Was ist angesagt?

Industrial Pharmacy-II (IP-II) Unit 2:- chapter:- 2 Technology Development an...
Industrial Pharmacy-II (IP-II) Unit 2:- chapter:- 2 Technology Development an...Industrial Pharmacy-II (IP-II) Unit 2:- chapter:- 2 Technology Development an...
Industrial Pharmacy-II (IP-II) Unit 2:- chapter:- 2 Technology Development an...Audumbar Mali
 
Supac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage FormSupac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage FormJubiliant Generics Limited
 
WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.
WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.
WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.GvDurgamani
 
Certificate of pharmaceutical product
Certificate of pharmaceutical productCertificate of pharmaceutical product
Certificate of pharmaceutical productAtul Bhombe
 
Pilot plant scaleup techniques used in pharmaceutical manufacturing
Pilot plant scaleup techniques used in pharmaceutical manufacturingPilot plant scaleup techniques used in pharmaceutical manufacturing
Pilot plant scaleup techniques used in pharmaceutical manufacturingSunil Boreddy Rx
 
Technology Transfer Related Documents.pptx
Technology Transfer Related Documents.pptxTechnology Transfer Related Documents.pptx
Technology Transfer Related Documents.pptxAfroj Shaikh
 
Technology Transfer in Pharma Industry
Technology Transfer in Pharma IndustryTechnology Transfer in Pharma Industry
Technology Transfer in Pharma Industrynaseebbasha
 
Regulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalRegulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalShagufta Farooqui
 
Technology development & transfer by devill
Technology development & transfer by devillTechnology development & transfer by devill
Technology development & transfer by devillSnake EYE
 
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )JAYACHANDRA AKUTHOTA
 
Scale up post approval changes
Scale up post approval changesScale up post approval changes
Scale up post approval changesROHIT
 
Technology transfer.pptx
Technology transfer.pptxTechnology transfer.pptx
Technology transfer.pptxAshwiniBhoir2
 
Pharmaceutical Licecnsing authorites of india
Pharmaceutical Licecnsing authorites of indiaPharmaceutical Licecnsing authorites of india
Pharmaceutical Licecnsing authorites of indiaAtul Bhombe
 

Was ist angesagt? (20)

Supac
SupacSupac
Supac
 
Industrial Pharmacy-II (IP-II) Unit 2:- chapter:- 2 Technology Development an...
Industrial Pharmacy-II (IP-II) Unit 2:- chapter:- 2 Technology Development an...Industrial Pharmacy-II (IP-II) Unit 2:- chapter:- 2 Technology Development an...
Industrial Pharmacy-II (IP-II) Unit 2:- chapter:- 2 Technology Development an...
 
Supac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage FormSupac - Guidance for Immediate Release Dosage Form
Supac - Guidance for Immediate Release Dosage Form
 
WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.
WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.
WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.
 
Certificate of pharmaceutical product
Certificate of pharmaceutical productCertificate of pharmaceutical product
Certificate of pharmaceutical product
 
Pilot plant scaleup techniques used in pharmaceutical manufacturing
Pilot plant scaleup techniques used in pharmaceutical manufacturingPilot plant scaleup techniques used in pharmaceutical manufacturing
Pilot plant scaleup techniques used in pharmaceutical manufacturing
 
Nda
NdaNda
Nda
 
Technology Transfer Related Documents.pptx
Technology Transfer Related Documents.pptxTechnology Transfer Related Documents.pptx
Technology Transfer Related Documents.pptx
 
Technology Transfer in Pharma Industry
Technology Transfer in Pharma IndustryTechnology Transfer in Pharma Industry
Technology Transfer in Pharma Industry
 
Granularity of TT Process.pdf
Granularity of TT Process.pdfGranularity of TT Process.pdf
Granularity of TT Process.pdf
 
Regulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalRegulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug Approval
 
Master formula record
Master formula recordMaster formula record
Master formula record
 
Technology development & transfer by devill
Technology development & transfer by devillTechnology development & transfer by devill
Technology development & transfer by devill
 
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
REGULATORY AFFAIRS ( IP-2 / UNIT 3 )
 
Scale up post approval changes
Scale up post approval changesScale up post approval changes
Scale up post approval changes
 
ICH guidelines (Q,S,E,M)
ICH guidelines (Q,S,E,M)ICH guidelines (Q,S,E,M)
ICH guidelines (Q,S,E,M)
 
Quality Risk Management
Quality Risk ManagementQuality Risk Management
Quality Risk Management
 
WHO Guidance on Technology Transfers
WHO Guidance on Technology TransfersWHO Guidance on Technology Transfers
WHO Guidance on Technology Transfers
 
Technology transfer.pptx
Technology transfer.pptxTechnology transfer.pptx
Technology transfer.pptx
 
Pharmaceutical Licecnsing authorites of india
Pharmaceutical Licecnsing authorites of indiaPharmaceutical Licecnsing authorites of india
Pharmaceutical Licecnsing authorites of india
 

Ähnlich wie Supac

Supac - Guidance for Modified Release Dosage Form
Supac - Guidance for Modified Release Dosage FormSupac - Guidance for Modified Release Dosage Form
Supac - Guidance for Modified Release Dosage FormJubiliant Generics Limited
 
Supac For Modified Relese Dosage Form
Supac For Modified Relese Dosage FormSupac For Modified Relese Dosage Form
Supac For Modified Relese Dosage FormMalay Jivani
 
Supac and post marketing serveillance
Supac and post marketing serveillanceSupac and post marketing serveillance
Supac and post marketing serveillanceBhavyaJivrajani
 
Scale – Up & Post Approval Changes
Scale – Up & Post Approval ChangesScale – Up & Post Approval Changes
Scale – Up & Post Approval ChangesVAIBHAV SHENDE
 
scaleup and post approval modification.pptx
scaleup and post approval modification.pptxscaleup and post approval modification.pptx
scaleup and post approval modification.pptxPankajSharma446574
 
Product lifecycle management
Product lifecycle managementProduct lifecycle management
Product lifecycle managementgarimasaini33
 
Supac guidelines for mr tablets
Supac guidelines for mr tabletsSupac guidelines for mr tablets
Supac guidelines for mr tabletsAmruthaSanthoshini
 
IN VIVO AND SCALE-UP PROCESS APPROVAL CHANGES.pptx
IN VIVO AND  SCALE-UP  PROCESS APPROVAL CHANGES.pptxIN VIVO AND  SCALE-UP  PROCESS APPROVAL CHANGES.pptx
IN VIVO AND SCALE-UP PROCESS APPROVAL CHANGES.pptxPawanDhamala1
 
Scale up Process and Post Approval Changes
Scale up Process and Post Approval ChangesScale up Process and Post Approval Changes
Scale up Process and Post Approval ChangesPrajaktaPatil890246
 
SUPAC, BACPAC, Post Marketing Surveillance
SUPAC, BACPAC, Post Marketing SurveillanceSUPAC, BACPAC, Post Marketing Surveillance
SUPAC, BACPAC, Post Marketing SurveillanceMANIKANDAN V
 
Scale up and post approval changes
Scale up and post approval changesScale up and post approval changes
Scale up and post approval changesPriyaTalekar
 

Ähnlich wie Supac (20)

SUPAC
SUPACSUPAC
SUPAC
 
Supac - Guidance for Modified Release Dosage Form
Supac - Guidance for Modified Release Dosage FormSupac - Guidance for Modified Release Dosage Form
Supac - Guidance for Modified Release Dosage Form
 
SUPAC.pptx
SUPAC.pptxSUPAC.pptx
SUPAC.pptx
 
Supac For Modified Relese Dosage Form
Supac For Modified Relese Dosage FormSupac For Modified Relese Dosage Form
Supac For Modified Relese Dosage Form
 
SUPAC-IR.ppt
SUPAC-IR.pptSUPAC-IR.ppt
SUPAC-IR.ppt
 
Supac and post marketing serveillance
Supac and post marketing serveillanceSupac and post marketing serveillance
Supac and post marketing serveillance
 
2. SUPAC.pdf
2. SUPAC.pdf2. SUPAC.pdf
2. SUPAC.pdf
 
Scale – Up & Post Approval Changes
Scale – Up & Post Approval ChangesScale – Up & Post Approval Changes
Scale – Up & Post Approval Changes
 
SUPAC.pptx
SUPAC.pptxSUPAC.pptx
SUPAC.pptx
 
scaleup and post approval modification.pptx
scaleup and post approval modification.pptxscaleup and post approval modification.pptx
scaleup and post approval modification.pptx
 
Product lifecycle management
Product lifecycle managementProduct lifecycle management
Product lifecycle management
 
Supac
SupacSupac
Supac
 
SUPAC PART-1
SUPAC PART-1SUPAC PART-1
SUPAC PART-1
 
Supac guidelines for mr tablets
Supac guidelines for mr tabletsSupac guidelines for mr tablets
Supac guidelines for mr tablets
 
IN VIVO AND SCALE-UP PROCESS APPROVAL CHANGES.pptx
IN VIVO AND  SCALE-UP  PROCESS APPROVAL CHANGES.pptxIN VIVO AND  SCALE-UP  PROCESS APPROVAL CHANGES.pptx
IN VIVO AND SCALE-UP PROCESS APPROVAL CHANGES.pptx
 
Scale up Process and Post Approval Changes
Scale up Process and Post Approval ChangesScale up Process and Post Approval Changes
Scale up Process and Post Approval Changes
 
SUPAC, BACPAC, Post Marketing Surveillance
SUPAC, BACPAC, Post Marketing SurveillanceSUPAC, BACPAC, Post Marketing Surveillance
SUPAC, BACPAC, Post Marketing Surveillance
 
Supac
SupacSupac
Supac
 
Scale up and post approval changes
Scale up and post approval changesScale up and post approval changes
Scale up and post approval changes
 
documentation in pharmaceutical industry
documentation in pharmaceutical industrydocumentation in pharmaceutical industry
documentation in pharmaceutical industry
 

Mehr von Sayeda Salma S.A.

Tumor targeting 2nd presentation
Tumor targeting 2nd presentationTumor targeting 2nd presentation
Tumor targeting 2nd presentationSayeda Salma S.A.
 
History of computers in pharmaceutical research
History of computers in pharmaceutical researchHistory of computers in pharmaceutical research
History of computers in pharmaceutical researchSayeda Salma S.A.
 
Herbal ingredients in oral care
Herbal ingredients in oral careHerbal ingredients in oral care
Herbal ingredients in oral careSayeda Salma S.A.
 
Formulation and processing factors
Formulation and processing factorsFormulation and processing factors
Formulation and processing factorsSayeda Salma S.A.
 
Descriptive versus mechanistic modelling
Descriptive versus mechanistic modellingDescriptive versus mechanistic modelling
Descriptive versus mechanistic modellingSayeda Salma S.A.
 
Biological process involved in drug targetting
Biological process involved  in drug targettingBiological process involved  in drug targetting
Biological process involved in drug targettingSayeda Salma S.A.
 
Liposome based protien and peptide delivery
Liposome based protien and peptide deliveryLiposome based protien and peptide delivery
Liposome based protien and peptide deliverySayeda Salma S.A.
 
Evaluation of buccal drug delivery system
Evaluation of buccal drug delivery systemEvaluation of buccal drug delivery system
Evaluation of buccal drug delivery systemSayeda Salma S.A.
 
Transdermal drug delivery system
Transdermal drug delivery systemTransdermal drug delivery system
Transdermal drug delivery systemSayeda Salma S.A.
 

Mehr von Sayeda Salma S.A. (20)

Tumor targeting 2nd presentation
Tumor targeting 2nd presentationTumor targeting 2nd presentation
Tumor targeting 2nd presentation
 
Targetted drug delivery
Targetted drug deliveryTargetted drug delivery
Targetted drug delivery
 
Rheological additives
Rheological additivesRheological additives
Rheological additives
 
History of computers in pharmaceutical research
History of computers in pharmaceutical researchHistory of computers in pharmaceutical research
History of computers in pharmaceutical research
 
Herbal ingredients in oral care
Herbal ingredients in oral careHerbal ingredients in oral care
Herbal ingredients in oral care
 
Guidelines for emollients
Guidelines for emollientsGuidelines for emollients
Guidelines for emollients
 
Formulation and processing factors
Formulation and processing factorsFormulation and processing factors
Formulation and processing factors
 
Emollients
EmollientsEmollients
Emollients
 
Descriptive versus mechanistic modelling
Descriptive versus mechanistic modellingDescriptive versus mechanistic modelling
Descriptive versus mechanistic modelling
 
Cleansing and care needs
Cleansing and care needsCleansing and care needs
Cleansing and care needs
 
Brain specific delivery
Brain specific deliveryBrain specific delivery
Brain specific delivery
 
Biological process involved in drug targetting
Biological process involved  in drug targettingBiological process involved  in drug targetting
Biological process involved in drug targetting
 
Acne vulgaris [autosaved]
Acne vulgaris [autosaved]Acne vulgaris [autosaved]
Acne vulgaris [autosaved]
 
Budget and cost control
Budget and cost controlBudget and cost control
Budget and cost control
 
Liposome based protien and peptide delivery
Liposome based protien and peptide deliveryLiposome based protien and peptide delivery
Liposome based protien and peptide delivery
 
Evaluation of buccal drug delivery system
Evaluation of buccal drug delivery systemEvaluation of buccal drug delivery system
Evaluation of buccal drug delivery system
 
Parenteral formulations
Parenteral formulationsParenteral formulations
Parenteral formulations
 
Pms
PmsPms
Pms
 
Standard deviation
Standard deviationStandard deviation
Standard deviation
 
Transdermal drug delivery system
Transdermal drug delivery systemTransdermal drug delivery system
Transdermal drug delivery system
 

Kürzlich hochgeladen

Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 

Kürzlich hochgeladen (20)

Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 

Supac

  • 2. What is supac ? In the process of developing the new product , the batch size used in earliest human studies are small. The sizes of the batch is gradually increased(scale up). The scale up and the changes made after approval in the composition, manufacturing process , manufacturing equipment and change of site have become known as scale up and post approval changes (supac).
  • 3. SUPAC The FDA has issued various guidance for supac changes designated as: Supac-IR ( for immediate release solid oral dosage form). Supac-MR (for modified release solid oral dosage form). Supac-SS (for non sterile semisolid dosage form including creams, ointments, gels and lotions).
  • 4. Supac guidelines-define Level of changes • Minor changes • Moderate changes • Major changes filing • Annual report • Changes being affected supplement • Prior approval supplement tests • Application/compendial tests • In-vitro dissolution/release • In-vivo
  • 5. Level of changes Likelihood of impact on formulation quality and performance: • Level 1: Those changes that are unlikely to have any detectable impact on formulation quality and performance. • Example- Changes in the colour, flavours, Changes In the excipient expressed as percentage (w/w) of total formulation, less than or equal to the following range .
  • 6. • Level2: Changes are those that could have significant impact on the formulation quality and performance. • Example -Changes in the technical grade of excipient (Avicel PH102 vs Avicel PH200) Changes expressed as percent (w/w of total formulation) .
  • 7. • Level3:  Level 3 : changes are those that are likely to have significant impact on formulation quality and performance. Example -Any qualitative or quantitative excipient changes a narrow therapeutic drug beyond the range for level 1 and All other drug not meeting the dissolution criteria as level 2.
  • 8. These guidelines provide recommdation for post approval changes in: • In component or compostion • The site of manufacture • The scale up of manufacture • The manufacturing(process and equipment)
  • 9. Component and composition changes SUPAC-IR:  Focus on changes in the amount of excipients in the drug product. SUPAC-MR:  Excipient critical or non critical to the drug release. - Changes in non release controlling excipients - Changes in release controlling excipients. SUPAC-SS:  Changes in preservative.
  • 11. SUPAC-IR • 1)Focus on the changes in amount of excipients in the drug product. • 2)Not focus on change in the amount of the drug substance .
  • 12. LEVEL CLASSIFICATION EXCIPIENT RANGES (%w/w of total formulation) TEST DOCUMENTATION FILING DOCUMENTA TION 1) • Delition or partial delition of an ingredient (colour , flavor or change in ingredient of the ink). • -Changes in excipients, expressed as % (w/w) of total formulation, less than or equal to excipient.  Filler  ±5 Disintegrant  Starch  ±1 Binder  ±0.5 Lubricant  Calcium (Ca)or Magnesium  (Mg) Stearate ±0.25  stability  Application/Co mpendial requirements  Annual report
  • 13. LEVEL CLASSIFICATION EXCIPIENT RANGES (%w/w of total formulation) TEST DOCUMENTATION FILING DOCUMEN TATION 2)  Change in technical grade of excipient.  Changes in excipients, expressed as % (w/w) of total formulation, greater than Level 1 changes.  Filler  ±10 Disintegrant  Starch  ±6 Other  ±1 Binder  ±1 Lubricant  Calcium (Ca) or  Magnesium (Mg)  Stearate ±0.5  Other ±2 Glidant Talc ±2 Other ±0.2  -stability application/co mpendial requirements.  Dissolution data depends on solubility, therapeutic range and permeability.  Case A(hp-hs)  Case B(lp-hs)  Case C(hp-ls) •Prior approval supplement •Annual report
  • 14. LEVEL CLASSIFICATION TEST DOCUMENTATION FILING DOCUMENTATION 3)  Higher than SUPAC- IR.  Level 1 and Level 2 excipient ranges.  stability application/compend ial requirements.  Case B dissolution profile (Multi-point dissolution profile in the application /compendial medium at 15, 30, 45, 60, and 120 minutes or until an asymptote is reached for the proposed and currently accepted formulation).   Biostudy or IVIVC •Prior approval supplement. •Annual report.
  • 16. SUPAC-MR Components and composition of non-release controlling excipient and release controlling excipient.  Focuses on changes to non-release controlling excipients.  Changes in components or composition that have the effect of adding a new excipient or deleting an excipient are defined at level 3.
  • 17. Non-release controlling excipient LEVEL CLASSIFICATION TEST DOCUMENTATION FILING 1)  Delition or partial delition of an ingredient –up to SUPAC-IR Level 1 excipient ranges.  stability- application/compen dial requirements.  Annual report
  • 18. LEVEL 2 2)  change in technical grade of excipients  up to SUPAC-IR Level 2 excipient ranges  stability application/compen dial requirements.  Multi-point dissolution profiles (15,30,45,60 & 120 min) USP buffer media at pH 4.57.5 for extended release) Three different Media (e.g., Water, 0.1N HCl, and USP buffer media at Ph 4.5 And 6.8 for delayed release) •Prior approval supplement. •Annual report
  • 19. LEVEL 3 3)  Higher than SUPAC-IR Level 1 and Level 2 excipient ranges.  -stability application/compen dial requirements.  Biostudy or IVIVC  Prior approval supplement
  • 20. SUPAC-MR (release controlling excipient) LEVEL CLASSIFICATION TEST DOCUMENTATION FILING DOCUMENTATION 1)  ≤ 5% w/w change based on total release controlling excipient content.  No other changes  Stability  application/compendi al requirements  Annual report
  • 21. LEVEL 2 2)  change in technical grade of excipients.  ≤ 10% w/w change based on total release controlling excipient content.  stability application/compendi al requirements.  Multi-point dissolution profiles (15,30,45,60 & 120 min) USP buffer pH 4.5-7.5 for extended release) Three different Media (e.g., Water, 0.1N HCl, and USP buffer media at Ph 4.5 And 6.8 for DR release)  Prior approval supplement  Annual report
  • 23. SUPAC-SS • for non sterile semisolid dosage form including creams , ointments , gels and lotions.
  • 24. SUPAC-SS (Components and composition) LEVEL CLASSIFICATION TEST DOCUMENTATION FILING DOCUMENTATION 1)  Delition or partial delition of an ingredient.  change in supplier or technical grade of any other excipient.  Up to 5 % change in approved amount of ingredient  Stability  application/ compendial requirements  Annual report
  • 25. LEVEL 2 2)  Upto >5 % and ≤ 10 % change in approved amount of ingredient.  Change in particle size distribution of the drug substance, if the drug is in Suspension.  change in supplier or technical grade of any other excipient  stability application/compe ndial requirements  in vitro release test  Changes being effected supplement  Annual report
  • 26. LEVEL 3 3)  change in approved amount of ingredient.  Change in crystalline form of ingredient  Stability  application/comp endial requirements  Prior approval supplement
  • 27. SUPAC-SS (preservative) LEVEL CLASSIFICATION TEST DOCUMENTATION FILING DOCUMENTATION 1) Quantitatively 10% or less change in the approved amount of preservative.  application/comp endial requirements  Preservative effectiveness test at lowest specified preservative level Annual report
  • 28. LEVEL 2 2)  10% -20 % change in the approved amount of preservative  application/comp endial requirements.  Preservative effectiveness test at lowest specified preservative level  Changes being effected supplem ent  Annual report
  • 29. LEVEL 3 3)  > 20% change in the approved amount of preservative (including deletion) or use of a different preservative.  application/compen dial requirements - executed batch records.  For new preservative, analytical method for identification and assay validation studies.  Preservative effectiveness test at lowest specified preservative.  Prior approval supplement  Annual report
  • 30. Site changes It includes the changes in location of the site of manufacturing facilities for both company owner and contract manufacturer. It does not include scale up
  • 31. LEVEL 1 LEVEL CLASSIFICATION TEST DOCUMENTATION FILING DOCUMENTATION 1)  Site change within a single facility.  No change in SOP, environmental conditions or equipment's used.  Common personnel's  application/co mpendial requirements Annual report
  • 32. Level 2 2)  Same continuous campus  Common personnel  No other changes  application/compendial requirements.  Notification of Location of new site  Updated batch records.  SUPAC – MR : Multi-point dissolution profiles (15,30,45,60 & 120 min) USP buffer media at pH 4.5-7.5 for extended release) Three different Media (e.g., Water, 0.1N HCl, and USP buffer media at Ph 4.5 And 6.8 for delayed release)until 80% of Drug Released.  Annual report  Changes being Effected Supplement
  • 33. LEVEL 3 3)  Different campus  Different personnel  application/compendial requirements  Notification of Location of new site  Updated batch record  SUPAC –IR : Multi-point dissolution profile in the application and compendial medium  SUPAC – MR : Multi-point dissolution profiles (15,30,45,60 & 120 min) USP buffer media at pH 4.5-7.5 for extended release) Three different Media (e.g., Water, 0.1N HCl, and USP buffer media at Ph 4.5 And 6.8 for delayed release).  Annual report  Prior approval supplement
  • 34. Change in batch size (scale up of manufacture) Post approval changes in the size of a batch from the pivotal/pilot scale biobatch material to larger or smaller production. Post Scale down below 1,00,000 dosage units is not covered by this guideline. Scale down Scale up changes should be properly validated and if needed, inspected by appropriate agency personnel. Scale up
  • 35. Level 1 LEVEL CLASSIFICATION TEST DOCUMENTATION FILING DOCUMENTATION 1)  Change in batch size, up to and including a factor of 10 times the size of the pilot/biobatch  Updated batch records application/compendial requirements stability Annual report
  • 36. Level 2 2)  Changes in batch size beyond a factor of ten times the size of the pilot or biobatch  No other changes  -Updated batch records - application/compendial requirements  Stability  SUPAC –IR Multi-point dissolution profiles.  SUPAC – MR -Multi-point dissolution profiles in multiple medias (e.g., USP buffer media at pH 4.5-7.5 for extended release) three other media (e.g., Water, 0.1N HCl, and USP buffer media at Ph 4.5 And 6.8 for delayed o Annual report o Changes being effected by suppleme nt
  • 37. MANUFACTURING CHANGES (equipment) LEVEL CLASSIFICATION TEST DOCUMENTATION FILING DOCUMENTATION 1)  Alternate equipment of same design and principles Automated equipment's  Updated batch records  application/compendial requirements stability Annual report
  • 38. LEVEL 2 2)  Change to equipment of different design and principle  Updated batch records application/compendial requirements  Stability  SUPAC –IR Multi-point dissolution profiles in multiple medias  SUPAC – MR -Multi-point dissolution profiles in multiple medias  Annual report  Changes being Effected Suppleme nt
  • 39. MANUFACTURING CHANGES (PROCESS)  LEVEL CLASSIFICATION TEST DOCUMENTATION FILING DOCUMENTATION 1)  Adjustment of equipment operating conditions (operating speeds, mixing times)  Within approved application ranges  Updated batch records  application/compendial requirements  Stability Annual report
  • 40. LEVEL 2 2)  Adjustment of equipment operating conditions (operating speeds, mixing times)  Beyond approved application ranges  SUPAC – SS Change in the process of combining two phases  -Updated batch records - application/compendial requirements  Stability  SUPAC-IR Multi-point dissolution profile.  SUPAC-MR -Multi-point dissolution profiles in multiple medias (e.g., USP buffer media at pH 4.5-7.5 for extended release) three other media (e.g., Water, 0.1N HCl, and USP buffer media at Ph 4.5 And 6.8 for delayed release).  SUPAC-SS In vitro release test Documentation.  Annual report  Changes being Effected Suppleme nt
  • 41. LEVEL 3 3)  Changes in the type of process used (e.g. wet granulation to direct compressio n  Updated batch records - application/compendial requirements -Stability - Biostudy or IVIVC.  SUPAC-IR Multi-point dissolution profile.  SUPAC-MR Multi-point dissolution profiles in multiple medias (e.g., USP buffer media at pH 4.5-7.5 for extended release) three other media (e.g., Water, 0.1N HCl, and USP buffer media at Ph 4.5 And 6.8 for delayed release)  Prior approval supplement  Annual report
  • 42. LIMITATIONS OF SUPAC • Supac has not been updated ( 1995/97 for main guidelines ) • Does not discuss multiple changes • Does not cover modified equipment • Must be used in conjunction with other references ex: excipient handbook.